Aerocrine AB (STO:AEROB) today announced that Allergy & Asthma Specialists, P.C. has adopted Aerocrine's FENO technology for airway inflammation measurement as part of its clinical standardization on a system-wide basis. Allergy & Asthma Specialists, P.C. is the largest group practice in the Philadelphia region specializing in allergic disease, asthma and immunology. Allergists use FENO to diagnose eosinophilic airway inflammation in patients with non-specific respiratory symptoms, to predict patient response to corticosteroid therapy, as well as to optimize dosing and assess adherence to anti-inflammatory therapy.
Allergy & Asthma Specialists, P.C. has eight locations in Philadelphia and surrounding suburbs. "We pride ourselves at providing our patients with the most up to date and comprehensive care," said Dr. Robert Anolik, President of Allergy & Asthma Specialists, P.C. "Measurement of exhaled nitric oxide will enable us to provide optimal asthma management to our patients."
"We are delighted to have this prestigious group of Allergy and Asthma Specialists on board with FENO testing, providing personalized asthma management", said Kathy Hodgdon, Director of Sales & Marketing with Aerocrine. "In less than two minutes, this simple and inexpensive test makes it possible for physicians to better help patients living with asthma with appropriate therapy and disease control based on the patients' individual needs."
Asthma associated with memory issues in children